Skip to content

Effects of methimazole on the pharmacokinetics of itopride in humans

Effects of methimazole on the pharmacokinetics of itopride in humans

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNRC-11001183
Enrollment
Unknown
Registered
2011-01-02
Start date
2009-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

FMO3- MM:FMO3- MM
FMO3-WW:FMO3-WW

Sponsors

Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
19 Years to 26 Years

Inclusion criteria

Inclusion criteria: 1. Male, age > 18 years old; 2. Healthy subjects confirmed by medical history, a full clinical examination, and standard hematologic and blood chemistry laboratory tests before enrollment; 3. Voluntarily participated the study and signed informed contents forms; 4. Did not take any regular medication and were asked to refrain from consuming alcohol, grapefruit juice, coffee, green tea, any vitamins and nutritional supplements for 2 weeks before study commencement and throughout the study.

Exclusion criteria

Exclusion criteria: 1. With abnormal examinations parameters; 2. Smokers or drinkers; 3. Being treated with other drugs in two weeks

Design outcomes

Primary

MeasureTime frame
Aitopride UC 0-infinitus, Cmax, Tmax;

Countries

China

Contacts

Public ContactLan FAN
qwj8277@163.com+86 0731 84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026